Charles Schwab Investment Management Inc. Has $97.20 Million Stock Position in Royalty Pharma PLC (NASDAQ:RPRX)

Charles Schwab Investment Management Inc. trimmed its position in Royalty Pharma PLC (NASDAQ:RPRX) by 0.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,122,531 shares of the biopharmaceutical company’s stock after selling 9,097 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.54% of Royalty Pharma worth $97,204,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. increased its position in Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company’s stock worth $432,862,000 after purchasing an additional 5,069,127 shares during the period. Two Sigma Advisers LP increased its position in Royalty Pharma by 21.1% in the fourth quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company’s stock worth $93,703,000 after purchasing an additional 640,000 shares during the period. Victory Capital Management Inc. increased its position in Royalty Pharma by 270.4% in the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock worth $112,788,000 after purchasing an additional 2,644,923 shares during the period. Northern Trust Corp increased its position in Royalty Pharma by 12.8% in the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company’s stock worth $84,959,000 after purchasing an additional 376,619 shares during the period. Finally, GMT Capital Corp grew its position in shares of Royalty Pharma by 5.5% during the 4th quarter. GMT Capital Corp now owns 3,267,700 shares of the biopharmaceutical company’s stock worth $83,359,000 after buying an additional 170,200 shares during the period. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $35.86 on Wednesday. The firm has a market capitalization of $20.16 billion, a P/E ratio of 20.73, a PEG ratio of 2.36 and a beta of 0.55. Royalty Pharma PLC has a 1 year low of $24.05 and a 1 year high of $38.00. The business has a 50-day moving average of $35.80 and a 200-day moving average of $33.66. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 0.74.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%. The business had revenue of $578.67 million during the quarter, compared to analyst estimates of $750.06 million. On average, equities analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a $0.22 dividend. The ex-dividend date is Friday, August 15th. This represents a $0.88 annualized dividend and a dividend yield of 2.5%. Royalty Pharma’s payout ratio is currently 50.87%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on RPRX shares. Morgan Stanley boosted their target price on Royalty Pharma from $51.00 to $54.00 and gave the stock an “overweight” rating in a research report on Thursday, July 10th. Citigroup boosted their target price on Royalty Pharma from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, July 22nd. Finally, Wall Street Zen upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Saturday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus target price of $49.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.